Industrifonden invests in the rare disease company AO Pharma



Industrifonden has made a strategic investment in AO Pharma AB, a pharmaceutical company focusing on specialty products for patient groups with limited alternatives.

AO Pharma is led by an experienced team, including Jacob Gunterberg, previously partner at HealthCap, Jonas Hansson, former CEO of Wilson Therapeutics and venture partner at HealthCap, and Lars Olsson, a seasoned pharmaceutical developer. The founding team’s mission is to globally seek and develop niche products and projects for commercialization, initially focusing on the Nordics and over time expanding into European markets. The company is currently preparing the filing of a marketing authorization application for its first product.

“We are strong believers in the capabilities of this team, their potential to make significant impact in the rare disease area and to develop a growing business,” says Jonas Brambeck, Senior Investment Director of Industrifonden.

Peter Wolpert, CEO of Industrifonden, joins AO Pharma’s board of directors

“We have frequently cooperated and worked with Industrifonden in our previous careers and are happy to welcome them to AO Pharma in their capacity as a knowledgeable investor,” says Jonas Hansson, CEO of AO Pharma.

For more information about AO Pharma and its mission, visit ↗